Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

9.15USD
21 Sep 2018
Change (% chg)

$-0.30 (-3.17%)
Prev Close
$9.45
Open
$9.49
Day's High
$9.66
Day's Low
$9.03
Volume
279,410
Avg. Vol
159,233
52-wk High
$14.00
52-wk Low
$4.10

Select another date:

Thu, Sep 6 2018

Photo

Maryland charges Insys with engaging in deceptive opioid scheme

Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

UPDATE 2-Maryland charges Insys with engaging in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.

Maryland charges Insys engaged in deceptive opioid scheme

Sept 6 Maryland on Thursday charged Insys Therapeutics Inc with having engaged in deceptive practices that resulted in a powerful opioid medication the drugmaker produced that was meant for cancer patients being prescribed to other people.

REFILE-UPDATE 3-Insys to pay $150 mln to settle U.S. opioid kickback probe

Aug 8 Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Insys to pay $150 million to settle U.S. opioid kickback probe

Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Insys to pay $150 mln to settle DoJ probe

Aug 8 Insys Therapeutics said on Wednesday it had reached an agreement in principle with the U.S. Department of Justice to settle a civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.

FDA declines to approve Insys Therapeutic's opioid painkiller

Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

UPDATE 1-FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration had declined to approve its opioid painkiller, citing potential safety concerns.

U.S. to narrow opioid bribe case against Insys founder, others

BOSTON U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe a potent opioid after a federal judge questioned the scope of the indictment charging them.

Select another date: